TY - JOUR
T1 - The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia
AU - Ghani, Rohana Abdul
AU - Yaakob, Ismail Bin
AU - Wahab, Norasyikin Abdul
AU - Zainudin, Suehazlyn
AU - Mustafa, Norlaila
AU - Sukor, Norlela
AU - Mohamud, Wan Nazaimoon Wan
AU - Abdul Kadir, Khalid
AU - Kamaruddin, Nor Azmi
PY - 2013
Y1 - 2013
N2 - Background: Type 2 diabetes is associated with early development of endothelial dysfunction. Patients present with typical dyslipidemia (predominantly high levels of triglycerides [TG] and low levels of high-density lipoprotein cholesterol [HDL-C]) or mixed hypercholesterolemia (high levels of low-density lipoprotein cholesterol [LDL-C] and TG with low HDL-C). Normal levels include LDL-C <100 mg/dL, TG <135 mg/dL, and HDL-C > 40 mg/dL for men and >50 mg/dL for women. Objective: To determine the effects of 8 weeks administration of fenofibrate on inflammatory markers, metabolic parameters, and endothelial dysfunction. Methods: We administered micronized fenofibrate (Laboratories Fourneir S.A Dijon, France) daily for 8 weeks to 40 dyslipidemic, type 2 diabetes patients with equal numbers in each arm of the typical or mixed dyslipidemia groups. Noninvasive endothelial function assessments were performed and serum inflammatory markers obtained before and after treatment. Results: The typical group demonstrated significantly greater TG reduction and HDL-C increment, ie, 56 vs, 21.3 (P
AB - Background: Type 2 diabetes is associated with early development of endothelial dysfunction. Patients present with typical dyslipidemia (predominantly high levels of triglycerides [TG] and low levels of high-density lipoprotein cholesterol [HDL-C]) or mixed hypercholesterolemia (high levels of low-density lipoprotein cholesterol [LDL-C] and TG with low HDL-C). Normal levels include LDL-C <100 mg/dL, TG <135 mg/dL, and HDL-C > 40 mg/dL for men and >50 mg/dL for women. Objective: To determine the effects of 8 weeks administration of fenofibrate on inflammatory markers, metabolic parameters, and endothelial dysfunction. Methods: We administered micronized fenofibrate (Laboratories Fourneir S.A Dijon, France) daily for 8 weeks to 40 dyslipidemic, type 2 diabetes patients with equal numbers in each arm of the typical or mixed dyslipidemia groups. Noninvasive endothelial function assessments were performed and serum inflammatory markers obtained before and after treatment. Results: The typical group demonstrated significantly greater TG reduction and HDL-C increment, ie, 56 vs, 21.3 (P
UR - http://www.ncbi.nlm.nih.gov/pubmed/24079286
U2 - 10.1016/j.jacl.2013.04.004
DO - 10.1016/j.jacl.2013.04.004
M3 - Article
SN - 1933-2874
VL - 7
SP - 446
EP - 453
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 5
ER -